8:00 AM GMT, Dec 19, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.
Crofelemer regulatory update
Salix submitted an NDA to FDA for crofelemer to treat HIV-associated diarrhea. The submission comes just a month after Napo said it terminated a 2008 deal that gave Salix rights to crofelemer in North America,
Read the full 353 word article